Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers - Wikidata - wikimedia - TriplyDB

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

http://www.wikidata.org/entity/Q33417933

about

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.Sunitinib and other targeted therapies for renal cell carcinoma.Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients.A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors.The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer.Biomarkers for tyrosine kinase inhibitors in renal cell cancer.The VEGF pathway in cancer and disease: responses, resistance, and the path forward.Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib.PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma Basic research in kidney cancer.Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges.Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.GLI2 expression levels in radical nephrectomy specimens as a predictor of disease progression in patients with metastatic clear cell renal cell carcinoma following treatment with sunitinib.Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy.Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells.Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals.Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.Quantitative insight in utilizing circulating angiogenic factors as biomarkers for antiangiogenic therapy: systems pharmacology approach.Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma.Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.Acute renal failure during the "off" period after sunitinib administration: possible mechanism of vascular endothelial growth factor cascade hyperactivation.Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review.Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.Metastatic Renal Cell Carcinoma Presenting as a Bleeding Gastric Polyp

P2860

Q24606852-2D1C48CB-8739-4658-9A5E-F88B52439E48 Q33404547-4752D750-53F1-43B1-BCD7-D7AEE4E67D88 Q33474188-41B3CFF7-B24D-4831-8FCB-C52543717461 Q33587610-8F80CFFE-E083-4FD5-B85E-AAFAC0CFED6E Q33692402-83C39FE7-7D01-4FB7-A067-EC4DF7FFF9CD Q34554398-C583E034-DF0D-44D5-9E9C-21753A058E89 Q34621802-F9D48016-AD9D-4C51-9ECA-BE4678453976 Q35104052-A282A42C-C9E3-42E5-8213-CE6A87A1BE00 Q35861046-579780F7-BB83-4A94-8218-F9BE69FBCFD7 Q36275492-D3BDFF78-8082-4A89-8726-16EE4DB6B072 Q36420167-CD0CBFCC-28BF-423C-87C9-FFC690F81369 Q36450612-C83CFF1E-F1BD-4440-A1B7-03468C4C08CD Q36526512-EDBA421F-2796-4581-A62F-AB3711365DF4 Q37294895-E8794CFA-F2CD-457F-9CF1-ECADE71213EF Q37366059-40BE0845-5F05-4896-BA48-3C62857A5870 Q37559090-3C9ED4E4-BABF-4235-B092-72320B69CA52 Q37899447-9E418889-C5B1-430B-AB92-E069FAB0605E Q38071132-21541BF4-D6E3-4815-9498-BA37C8F77A2F Q38402997-91BCF9C4-CCE4-4504-9158-0421C49CAD89 Q38543085-E519D8B0-E54E-4056-BA27-70AA728303E1 Q38747792-B317CD38-239B-4D44-80D6-873D021CB42C Q38974204-222F9093-BCA1-4C97-9635-3E61A50F32C1 Q39348852-8D5890E5-6100-43FF-9082-98494DFB60F7 Q39396441-15090490-1DC9-4B6C-B633-7CD7F5F96754 Q39676953-A357184B-040E-4A55-BF90-65F0FE71E5C2 Q40836247-7ACA1E4A-F98B-4880-8432-011254E5CBA8 Q42418396-29128F43-0ED2-4D7C-AE82-17DAE4948A36 Q43725656-7B29D465-F919-40BB-8C96-8926F5EFE305 Q44049376-57368B56-D99F-4F45-A283-2295ECF7E239 Q45093247-C32EE1D9-AD3B-4A0B-A328-31B85F9F46C4 Q45745688-D9F57A57-E571-48E2-9C17-8E16539E0738 Q46024539-C0485C67-9CA8-4A89-A17A-6BCC6D0052BF Q46233598-3FA79482-3D37-46C5-BC0E-73AAB065D5CB Q54626855-E07005B2-DBD4-4904-86B8-EF7320B180C8 Q57060788-884074A6-4A42-4173-9258-5534CF8A6363

P2860

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

http://www.wikidata.org/entity/Q33417933

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Sunitinib treatment for patien ...... nd plasma angiogenesis markers

@ast

Sunitinib treatment for patien ...... nd plasma angiogenesis markers

@en

type

label

Sunitinib treatment for patien ...... nd plasma angiogenesis markers

@ast

Sunitinib treatment for patien ...... nd plasma angiogenesis markers

@en

prefLabel

Sunitinib treatment for patien ...... nd plasma angiogenesis markers

@ast

Sunitinib treatment for patien ...... nd plasma angiogenesis markers

@en

P1433

Q33417933-11609E97-3709-46B4-9027-8686ACF8F36A

P1476

Q33417933-318FF82A-ADD5-40F7-BE04-9F0918923B1A

P2093

Q33417933-026DB9AE-FAF2-4889-BA74-AE3878F7AE17

Q33417933-03669CEC-191D-4539-93C5-4A16B888193E

Q33417933-408D44B5-424A-4391-9CBB-1C5EC84DC6A5

Q33417933-5C403A8F-6F7C-49F9-8E50-C47888923193

Q33417933-655A1AEB-56BE-409C-9E7E-F9E533AAD4D9

Q33417933-B754C311-D4BB-4A7D-A23D-9CDFA73B0313

P2860

Q33417933-0F705A5C-3235-43A7-84F3-5A8E7735732C

Q33417933-12E860CD-A4AB-4C04-AF60-9343C003A564

Q33417933-2A342765-A9B7-41BC-8B39-286F5ED64502

Q33417933-3585AE36-ADFF-4509-8FB4-E625B3F781AF

Q33417933-48FD2C80-A7F0-4B5C-BCDE-11211019CBFF

Q33417933-6D8F5D1A-FDD7-4595-AABD-1C7E9D12067B

Q33417933-6DB2218F-19DA-499C-AB1B-207A78FDE420

Q33417933-739F6B03-5438-448A-BA91-094994015F8F

Q33417933-770E382B-A269-4576-9755-D7BFDBFC32BD

Q33417933-77931A33-D32A-46E1-B8DE-6FE69A3E6D27

P2888

Q33417933-979878B1-6BDD-4CA6-9BE5-B2D2A544AFAB

P304

Q33417933-85AFF226-AD00-400C-BA12-9D8CAE7FABA7

P31

Q33417933-8F67292D-4D65-454A-98E8-3ACCD665E896

P356

Q33417933-7C710710-314E-4454-AB24-12F2DBF715B5

P407

Q33417933-3324684D-9EC9-4CDF-9A7B-AE14B1D2C9D3

P478

Q33417933-95AD2E79-E516-404F-B810-3CE8A3B1FDCD

P577

Q33417933-6DC7A2BB-8119-4C2D-AC41-0436FE1467CC

P5875

Q33417933-56D24B14-3E5F-412C-BCBC-2B6B61C88487

P6179

Q33417933-6C6162B5-2793-4B78-8804-C004BA87DC2F

P698

Q33417933-F0CC8A74-E086-4801-88D3-7FC3B4383FA7

P932

Q33417933-4E79B35D-8F1F-4101-9A31-E3A5150FB171

P356

P1433

P1476

Sunitinib treatment for patien ...... nd plasma angiogenesis markers

@en

P2093

Alexandros H Kortsaris

http://www.w3.org/2001/XMLSchema#string

Charalambos Andreadis

http://www.w3.org/2001/XMLSchema#string

Despoina Mouratidou

http://www.w3.org/2001/XMLSchema#string

Konstantinos T Papazisis

http://www.w3.org/2001/XMLSchema#string

Loukas F Kontovinis

http://www.w3.org/2001/XMLSchema#string

Panagiota Touplikioti

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL

Cancer statistics, 2008

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Clinical trial designs for cytostatic agents: are new approaches needed?

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase

Identification of the von Hippel-Lindau disease tumor suppressor gene

Angiogenesis as a therapeutic target

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Clinical translation of angiogenesis inhibitors.

P2888

P304

82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-9-82

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24199317

http://www.w3.org/2001/XMLSchema#string

P6179

1051473159

http://www.w3.org/2001/XMLSchema#string

P698

19284623

http://www.w3.org/2001/XMLSchema#string

P932

2662874

http://www.w3.org/2001/XMLSchema#string